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egenerative medicine has begun to define a new perspec-
ive of future clinical practice. The U.S. Department of
ealth and Human Services report “2020: A New Vision—
Future for Regenerative Medicine” highlights that regen-
rative medicine is the vanguard of 21st-century health care
1). Patients and society increasingly expect that regenera-
ive medicine will lead to repair of diseased organs, injured
issues, or congenital anomalies. From pioneering success
ith bone marrow transplants for select hematological
isorders that are now standard of care (2) to the most
ecent advances in bioengineered stem cell platforms that
rovide unlimited sources of autologous pluripotent progen-
tors and broaden the scope of individualized diagnosis and
herapy (3), National Institutes of Health and National
cademies recognize regenerative medicine as a most prom-
sing core component of modern medical practice (4,5).
See pages 2232 and 2244
ithout the contribution of personalized products and
ervices emerging from regenerative medicine technology,
xperts caution that health care will face an escalation in
nefficient treatments and a rising global cost (6). Aimed
oward functional restoration of damaged tissues, not a mere
batement or moderation of symptoms, regenerative medi-
ine offers a “disruptive innovation” strategy uniquely poised
o add value and transform health care by providing tailored,
urative solutions for the unmet needs of our patients (7,8).
Tissue repair might provide a sustained therapeutic ad-
antage in a spectrum of conditions ranging from congenital
iseases to acquired, age-related pathologies. Applied in the
anagement of cardiovascular diseases, the rapidly devel-
ping regenerative medicine armamentarium promises sig-
ificant human health benefit with tangible outcomes for
ncreased quality of life and improved patient care, building
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Marriott Heart Disease Research Program, Division of Cardiovascular
iseases, Departments of Medicine, Molecular Pharmacology, and Experimental
herapeutics, and Medical Genetics, Mayo Clinic, Rochester, Minnesota.n breakthroughs in stem cell biology paired with successes
n transplant medicine. Maximizing potential return, how-
ver, mandates an integrated roadmap across the transla-
ional continuum of discovery-development-regulation-use
9) to ensure optimal application of regenerative medicine
lgorithms in practice.
he “R3” paradigm of repair. The framework for heart
epair relies on the general principles of “rejuvenation↔
eplacement↔regeneration” (Fig. 1). The “R3” paradigm of
herapeutic repair underscores the complementary strategies
hat conceptualize the scope of regenerative medicine (8).
rom heart muscle self-renewal (“rejuvenation”) to
ransplantation-based organ recycling (“replacement”) and,
ltimately, biogenesis of new tissue parts for de novo tissue
estoration (“regeneration”), the core components of the
epair triad offer natural or engineered means to ensure
issue homeostasis and achieve sustainable cure (Fig. 1).
Fundamental to the innate processes of cardiac tissue
ejuvenation is cardiomyocyte renewal, characterized by the
ngoing recruitment of resident progenitor pools within or
utside the heart (10,11). Self-repair mechanisms continu-
usly contribute to tissue homeostasis (12), although their
fficacy is variable among individuals and is compromised by
atient age, disease status, comorbidities, concomitant
harmacotherapy, as well as genetic, epigenetic, or ecoge-
etic influences. Radioisotope decay in the human body, a
emnant of nuclear bomb testing half-a-century ago, has
ecently offered an unprecedented opportunity to quantify
he birth date of single cardiomyocytes, indicating that
ne-half of the heart mass can be potentially renewed over
lifespan (13). Notably, stem cell contribution to postnatal
Figure 1 The “R3” Paradigm of Heart Repair
The “R3” triad of rejuvenation, replacement, and regeneration encompasses
processes underlying human heart repair. Rejuvenation refers to self-repair
through innate mechanisms of cardiomyocyte renewal, maintaining tissue
homeostasis. Replacement refers to transplantation of recycled parts for organ
substitution. Regeneration refers to engraftment and differentiation of progeni-
tor cells to restore tissue function through cell-based repair.
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May 18, 2010:2254–7 Regenerative Medicineeart formation has been validated by the self/non-self
himerism characteristic of patients after allogeneic trans-
lantation (14). Furthermore, stem cell loads increase in
ailing hearts, involving derivation of cardiomyocytes from
irculating as well as resident progenitor pools (15,16).
ejuvenation revitalizes the innate cardioprotective poten-
ial, yet in the context of large-scale destruction—as is the
ase after massive infarction—inherent repair mechanisms
re typically inadequate to salvage a deteriorating myocar-
ium (17).
Likewise, transplant medicine exploits a replacement
trategy as a valuable option to recycle used parts and restore
ailing organ function by means of exogenous substitutes—
t is limited, however, by donor shortage. There are an
stimated 2,500 heart transplants performed annually in the
.S.; yet over 100,000 additional patients would benefit
rom this lifesaving procedure in this country alone (18).
ue to the magnitude of such growing clinical need,
lternative strategies, including mechanical assist devices,
re increasingly explored. From the initial intent of “bridg-
ng” to transplant or recovery, success of this technology has
ed to newer indications, including permanent or “destina-
ion” therapy in selected patients. However, these significant
dvancements do not prevent the increasing pandemic of
efractory heart failure, currently managed by treatments to
imit symptomatic progression of incurable disease.
A boost in healing processes would stimulate the adaptive
esponse and promote adequate biogenesis of functional
issue to abrogate the progression of heart disease. Extrap-
lating from the paradigms of natural heart rejuvenation
nd transplant-based organ replacement, reactivation of
ndogenous and/or introduction of exogenous progenitor
ells into the injured heart would thereby offer a legitimate
arget to ameliorate the burden of disease. In this regard,
tem cell-based regeneration has revealed the next frontier
f medical therapy aimed at achieving structural and/or
unctional repair (19–21). The regenerative strategy refers
o engraftment of progenitor cells that requires in vivo
rowth and differentiation to establish a repair outcome
ithin the host environment. Collectively, approaches for
tem cell-based regenerative medicine are poised to drive
he evolution of medical sciences from traditional palliation
oward curative therapy by supplementing resident progen-
tor pools and facilitating chimeric healing of damaged
issues.
tem cell-based regeneration. Classified as “biologics,”
tem cells are a distinct class of medications produced by
eans of biological processes (22,23). In contrast to tradi-
ional pharmaceuticals, regenerative cytotherapy products
ontain viable cells as the active ingredient (24). Worldwide,
ver 3,000 patients with ischemic heart disease have re-
eived stem cell therapy in a clinical trial setting. Meta-
nalyses underscore feasibility and safety of stem cell-based
herapy and point to modest albeit variable improvement in
unctional parameters of recovery (25). These initial trials
ely on the use of first-generation products consisting of durified, natural human cells, typically in their native state,
uch as naïve mesenchymal stem cells isolated from the
atient’s bone marrow (20,26). Ongoing optimization and
dentification of the most appropriate cell source and cell
ype, means to enhance safety and effectiveness, selection of
atient populations most amenable to cell-based therapy,
deal timing of intervention, and most favorable route of
dministration are among the areas of focus to determine
he clinical scope and maximize benefit of cell-based therapy
n the management of cardiovascular disease (26–28).
Indeed, beyond initial concerns of feasibility and safety,
stablishing the functional and structural efficacy profiles of
pecific stem cell-based treatments is paramount to foster a
onscious application in future practice (28). It should be
oted that most clinical studies to date have tested hetero-
eneous cell populations associated with mixed results
25–28).
Head-to-head comparisons between stem cell platforms,
s exemplified in this issue of the Journal with the careful
haracterization of distinct adult progenitor populations
29,30), are critical in directing the selection of the most
aluable stem cell cytotypes and guiding the rational design
f next-generation clinical trials. These prototypic, well-
esigned studies rely on blinded, randomized, clinically
elevant approaches, and use high stringency parameters of
ifferentiation potential and repair outcome (29,30). Spe-
ifically, Armiña´n et al. (29) report that intramyocardial
ransplantation of human mesenchymal stem cells and
D34 hematopoietic cell progenitors—isolated from bone
arrow and umbilical cord blood, respectively—improve left
entricular function and increase cell proliferation and neoan-
iogenesis in healing infarcted myocardium. At equipotent
ose with regard to benefit on fractional shortening, mesen-
hymal stem cells were found superior in reducing infarct size
nd preventing ventricular remodeling in this nude rodent
isease model (29). The propensity of mesenchymal stem cells
o migrate from the site of injection to the infarcted zone
nd their additional aptitude to reduce collagen deposition
ere suggested contributors to favorable outcome (29).
ubois et al. (30), with selected porcine progenitor popu-
ations delivered by intracoronary infusion in a large animal
odel of acute myocardial infarction, report that autologous
ate-outgrowth endothelial progenitor cells are particularly
ffective in improving myocardial remodeling favoring
reater vascular density than naïve allogeneic mesenchymal
tem cell counterparts. Pro-angiogenic and paracrine
atrix-modulating effects were inferred on the basis of the
ene expression and protein release profiles of cultured
rogenitor cell populations, consistent with a greater neo-
ascularization potential of autologous late-outgrowth en-
othelial progenitor cells capable of secreting placental
rowth factor, a member of the vascular endothelial growth
actor family, and a key molecule in angiogenesis and
asculogenesis (30). The authors indicate that modes of
elivery, immunological status, and cardiomyogenic pre-
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ome (30).
Together these studies underscore the necessity for con-
inuous advancements in discovery science to increase the
nderstanding of stem cell biology in the context of the
ecipient diseased environment and the mechanisms of
yocardial repair. The nature of autologous versus alloge-
eic stem cell sources, the degree of cardiomyogenic versus
asculogenic potential, and the severity of disease-affected
egments are all critical variables raised by these studies that
eed consideration for a more efficient translation from
roof-of-concept studies to targeted application (29,30). In
act, it is anticipated that an increasing number of compar-
tive studies will be the focus topic of imminent basic and
linical studies in cardiovascular regenerative medicine.
ltimately, the rigor of comparative effectiveness outcome
nalysis with the potential to inform practice, improve care,
nd influence costs (31) applied across regenerative plat-
orms as well as between stem cell-based therapies and
urrent medical/surgical state-of-the-art management op-
ions will provide the cornerstone of future evidence-based
tandard of care and define reimbursement policy.
linical development. At this stage of product develop-
ent, proper pharmacodynamic and pharmacokinetic cer-
ifications are mandatory steps (21,22). Suitable markers of
iological activity are needed to adequately identify primary
harmacodymanic properties, even if the mechanism(s) of
ction remain only partially understood. In addition, estab-
ishing the optimal amounts and formulation of safe cell-
ased medicinal products needed to achieve the desired
ffects is a critical component of proving overall efficacy and
pplicability. Pharmacokinetic considerations include pa-
ameters of cell biodistribution, cell viability, and cell
roliferation following single- or multiple-dose regimens.
ngoing clinical studies are increasingly designed to pro-
ide an adequate demonstration of efficacy in the target
atient population, demonstrate an appropriate dose sched-
le for optimal therapeutic effect, and/or evaluate the
uration of therapeutic effect for risk-benefit assessment
26). Accordingly, clinical safety databases are developed to
nnotate adverse events, including procedural risk, immune
esponse, infection, malignant transformation, and long-
erm safety. Continuous rigor in product development will
e particularly needed as novel cell types, autologous or
llogeneic, naive or lineage-prespecified, natural or bioengi-
eered, are considered for human testing in the upcoming
ecade (21,32–34).
Cell-based medicinal products involve cell samples of
imited amounts, mostly to be used in a patient-specific
anner. This raises issues pertaining to quality-control
esting designed for each product under examination.
herefore the manufacture of cell-based medicinal products
ust be carefully designed and validated to ensure product
onsistency and traceability. Control and management of
anufacturing and quality-control testing are carried out
ccording to Good Manufacturing Practice requirements24). Screening for purity, potency, infectious contamina-
ion, and karyotype stability have become necessary ele-
ents (i.e., release criteria), in compliance with standard
perating practices for production and banking of cells used
s autologous or “off-the-shelf” allogeneic therapy. Accord-
ngly, the U.S. Food and Drug Administration and the
uropean Medicines Agency impose regulatory guidelines
or risk assessment, quality of manufacturing, preclinical and
linical development, and post-marketing surveillance of
tem cell biologics for translation from bench to bedside to
opulations (22,23).
ndividualized applications. Individualized medicine pro-
ides a powerful engine to tailor molecular profiles of
atients to maximize therapeutic specificity, reduce treat-
ent variability, and minimize adverse events (35). Insights
n the regenerative basis of cell, tissue, and organ function
nd their interface with the environment will increasingly
efine disease risk, identify processes mediating disease
usceptibility, or target mechanism-based therapies, thereby
roviding previously unanticipated opportunities for
atient-specific disease management. The emerging field of
egenerative medicine will thus grow in conjuncture with
he realization of the individualized medicine paradigm to
reate predictive, personalized, and preemptive solutions for
ailored patient-specific strategies. Individualized treatment
lgorithms for regenerative medicine will require quantifi-
ation of the inherent reparative potential to identify pa-
ients who would benefit from stem cell therapy (24). In this
ontext, the “stem cell load” specific to each patient will
erve as an “index for regenerative potential” that will prove
seful for prediction, diagnosis, prognosis, and targeting of
afe and effective therapies at the earliest stage of disease in
he new era of individualized regenerative medicine.
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